nivolumab,ipilimumab
bms
['lcsm,(-blcsm)', 'nivo', 'nsclc', 'nivolumab', 'sclc', 'increase,(-increased)', 'ipilimumab']
increase trial: single-arm, prospective phase ii trial with (borderline) resectable, t3-4n0 2 nsclc treated with ipilimumab plus nivolumab and
chemoradiotherapy followed by
surgery. n=27 pcr 63% mpr 79% #lcsm #esmo22 
Medical Oncology ?? HGU Gregorio Marañón?@myESMO Faculty ?? Lung Cancer - Mesothelioma - Thymoma?Power to the patients #endlungcancer #lcsm